1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014

Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014

  • March 2014
  • -
  • Global Markets Direct
  • -
  • 58 pages

Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014’, provides an overview of the Meningococcemia (Meningococcal Infections)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Meningococcemia (Meningococcal Infections), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Meningococcemia (Meningococcal Infections) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Meningococcemia (Meningococcal Infections)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Meningococcemia (Meningococcal Infections) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Meningococcemia (Meningococcal Infections) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Meningococcemia (Meningococcal Infections) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Meningococcemia (Meningococcal Infections)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Meningococcemia (Meningococcal Infections) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Meningococcemia (Meningococcal Infections) Overview 7
Therapeutics Development 8
Pipeline Products for Meningococcemia (Meningococcal Infections) - Overview 8
Pipeline Products for Meningococcemia (Meningococcal Infections) - Comparative Analysis 9
Meningococcemia (Meningococcal Infections) - Therapeutics under Development by Companies 10
Meningococcemia (Meningococcal Infections) - Therapeutics under Investigation by Universities/Institutes 12
Meningococcemia (Meningococcal Infections) - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Meningococcemia (Meningococcal Infections) - Products under Development by Companies 16
Meningococcemia (Meningococcal Infections) - Products under Investigation by Universities/Institutes 17
Meningococcemia (Meningococcal Infections) - Companies Involved in Therapeutics Development 18
GlaxoSmithKline plc 18
Biological E. Limited 19
Novartis AG 20
Panacea Biotec Limited 21
Wellstat Vaccines, LLC 22
Beijing Minhai Biotechnology Co., Ltd 23
Chongqing Zhifei Biological Products Co., Ltd. 24
Sanofi Pasteur SA 25
Meningococcemia (Meningococcal Infections) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Route of Administration 28
Assessment by Molecule Type 29
Drug Profiles 31
Meninge ACYW Conjugate - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Nimenrix - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Meningococcal ACW135 Vaccine (Plain) - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Meningococcal ACYW135 Vaccine (Plain) - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Meningococcal ACYW135X Vaccine (Plain) - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
MenABCWY Conjugate Vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Meningitis Vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Meningococcus CY Polysaccharide Conjugate Vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Meningococcal B Vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
ABC Meningococcal Vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Meningococcus B Vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Meningococcal Vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Meningococcal Conjugate Vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Meningococcemia (Meningococcal Infections) - Recent Pipeline Updates 46
Meningococcemia (Meningococcal Infections) - Dormant Projects 47
Meningococcemia (Meningococcal Infections) - Product Development Milestones 48
Featured News and Press Releases 48
Feb 24, 2014: Novartis provides second US university with Bexsero to help protect students and staff against potentially deadly meningitis B disease 48
Dec 09, 2013: Health Canada Approves Bexsero, the First Vaccine Available to Prevent Meningococcal Serogroup B 49
Jan 14, 2013: Novartis's Bexsero Shows Potential To Help Provide Broad Protection To Infants Against MenB In Phase III Clinical Trial 50
Dec 03, 2012: Sanofi Pasteur Canada Receives Health Canada Approval Of Menactra Meningococcal Conjugate Vaccine Indication For Infants 51
Nov 08, 2012: Sanofi Pasteur Announces Publication Of Pivotal Safety And Immunogenicity Data Of Menactra Vaccine For Infants And Toddlers 52
Feb 13, 2012: FDA Requests Additional Data On Novartis's Quadrivalent Meningococcal Conjugate Vaccine, Menveo For Expanded Use In Infants And Toddlers 53
Jun 16, 2011: FDA Accepts Novartis's Menveo sBLA For Review 53
May 12, 2011: Novartis Provides Update On Phase III Study Of Menveo Vaccine To Treat Meningococcal Disease 54
Apr 22, 2011: Sanofi Pasteur Announces FDA Approval Of Menactra Meningococcal Conjugate Vaccine Indication for Infants 55
Jan 31, 2011: FDA approves the Novartis quadrivalent meningococcal conjugate vaccine, Menveo, for use in children from 2 years of age 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Tables

Number of Products under Development for Meningococcemia (Meningococcal Infections), H1 2014 8
Number of Products under Development for Meningococcemia (Meningococcal Infections) - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Comparative Analysis by Unknown Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Meningococcemia (Meningococcal Infections) - Pipeline by GlaxoSmithKline plc, H1 2014 18
Meningococcemia (Meningococcal Infections) - Pipeline by Biological E. Limited, H1 2014 19
Meningococcemia (Meningococcal Infections) - Pipeline by Novartis AG, H1 2014 20
Meningococcemia (Meningococcal Infections) - Pipeline by Panacea Biotec Limited, H1 2014 21
Meningococcemia (Meningococcal Infections) - Pipeline by Wellstat Vaccines, LLC, H1 2014 22
Meningococcemia (Meningococcal Infections) - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2014 23
Meningococcemia (Meningococcal Infections) - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2014 24
Meningococcemia (Meningococcal Infections) - Pipeline by Sanofi Pasteur SA, H1 2014 25
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Stage and Target, H1 2014 27
Number of Products by Stage and Route of Administration, H1 2014 28
Number of Products by Stage and Molecule Type, H1 2014 30
Meningococcemia (Meningococcal Infections) Therapeutics - Recent Pipeline Updates, H1 2014 46
Meningococcemia (Meningococcal Infections) - Dormant Projects, H1 2014 47

List of Figures

Number of Products under Development for Meningococcemia (Meningococcal Infections), H1 2014 8
Number of Products under Development for Meningococcemia (Meningococcal Infections) - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Top 10 Molecule Type, H1 2014 29
Number of Products by Stage and Top 10 Molecule Type, H1 2014 30

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy
Vaccine
Infectious Disease

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.